224 related articles for article (PubMed ID: 10172083)
1. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.
Luce BR; Singer JW; Weschler JM; Buckner CD; Sheingold SH; Shannon-Dorcy K; Appelbaum FR; Nemunaitis J
Pharmacoeconomics; 1994 Jul; 6(1):42-8. PubMed ID: 10172083
[TBL] [Abstract][Full Text] [Related]
2. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
Nemunaitis J; Rabinowe SN; Singer JW; Bierman PJ; Vose JM; Freedman AS; Onetto N; Gillis S; Oette D; Gold M
N Engl J Med; 1991 Jun; 324(25):1773-8. PubMed ID: 1903847
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.
Rabinowe SN; Neuberg D; Bierman PJ; Vose JM; Nemunaitis J; Singer JW; Freedman AS; Mauch P; Demetri G; Onetto N
Blood; 1993 Apr; 81(7):1903-8. PubMed ID: 8461475
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma.
Link H; Boogaerts MA; Carella AM; Ferrant A; Gadner H; Gorin NC; Harabacz I; Harousseau JL; Hervé P; Holldack J
Blood; 1992 Nov; 80(9):2188-95. PubMed ID: 1421390
[TBL] [Abstract][Full Text] [Related]
5. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
[TBL] [Abstract][Full Text] [Related]
6. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.
Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Philip T
Blood; 1992 Sep; 80(5):1149-57. PubMed ID: 1515637
[TBL] [Abstract][Full Text] [Related]
8. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V
Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) following autologous marrow transplantation in man.
Appelbaum FR; Nemunaitis J
Behring Inst Mitt; 1988 Aug; (83):145-8. PubMed ID: 3071330
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Madero L; Díaz MA; Ortega JJ; Olive T; Martínez A; Badell I; Muñoz A; Gómez P
Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
[TBL] [Abstract][Full Text] [Related]
11. [Hematopoietic growth factor (GM-CSF) after autologous bone marrow transplantation. A randomized, double-blind, multicenter study in 91 cases of non-Hodgkin's malignant lymphomas].
Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Lemarié JC
Presse Med; 1993 Jan; 22(3):109-20. PubMed ID: 8493215
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer.
Nemunaitis J; Buckner CD; Dorsey KS; Willis D; Meyer W; Appelbaum F
Am J Clin Oncol; 1998 Aug; 21(4):341-6. PubMed ID: 9708630
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
Kaku K; Takahashi M; Moriyama Y; Nakahata T; Masaoka T; Yoshida Y; Shibata A; Kaneko T; Miwa S
Leuk Lymphoma; 1993 Oct; 11(3-4):229-38. PubMed ID: 8260897
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
[TBL] [Abstract][Full Text] [Related]
16. The use of recombinant human granulocyte-macrophage colony stimulating factor in autologous bone marrow transplantation.
Nemunaitis J; Singer JW
Am J Clin Oncol; 1991; 14 Suppl 1():S15-8. PubMed ID: 2048559
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
Richard C; Baro J; Bello-Fernandez C; Hermida G; Calavia J; Olalla I; Alsar MJ; Loyola I; Cuadrado MA; Iriondo A
Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.
O'Day SJ; Rabinowe SN; Neuberg D; Freedman AS; Soiffer RJ; Spector NA; Robertson MJ; Anderson K; Whelan M; Pesek K
Blood; 1994 May; 83(9):2707-14. PubMed ID: 8167349
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
